CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-05 | Michaelson Jennifer Chief Scientific Officer | Option exercise 10b5-1 | +4,000 | $4.30 | $17K | 174,844 |
| 2026-05-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −7,800 | $14.60 | $114K | 167,044 |
| 2026-05-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −200 | $15.58 | $3K | 166,844 |
| 2026-05-05 | Michaelson Jennifer Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 116,987 | ||
| 2026-03-05 | Michaelson Jennifer Chief Scientific Officer | Option exercise 10b5-1 | +4,000 | $4.30 | $17K | 178,844 |
| 2026-03-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −8,000 | $15.68 | $125K | 170,844 |
| 2026-03-05 | Michaelson Jennifer Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 120,987 | ||
| 2026-02-25 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −1,780 | $14.14 | $25K | 174,844 |
| 2026-02-24 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −3,601 | $14.47 | $52K | 176,624 |
| 2026-02-24 | AHMED NADIM President and CEO | Sale | −13,515 | $14.47 | $196K | 390,803 |
| 2026-02-24 | Jones Jeffrey Alan Chief Medical Officer | Sale | −4,582 | $14.47 | $66K | 159,968 |
| 2026-02-24 | SUMER JACQUELYN L Chief Legal Officer | Sale | −3,601 | $14.47 | $52K | 128,089 |
| 2026-02-23 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −1,752 | $13.99 | $25K | 180,225 |
| 2026-02-20 | Fenton Mary Kay Chief Financial Officer | Sale | −4,398 | $13.62 | $60K | 126,380 |
| 2026-02-20 | Jones Jeffrey Alan Chief Medical Officer | Sale | −4,982 | $13.62 | $68K | 164,550 |
| 2026-02-20 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −3,742 | $13.62 | $51K | 181,977 |
| 2026-02-20 | Michaelson Jennifer Chief Scientific Officer | Option exercise 10b5-1 | +8,000 | $4.30 | $34K | 189,977 |
| 2026-02-20 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −8,000 | $14.30 | $114K | 181,977 |
| 2026-02-20 | Michaelson Jennifer Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 124,987 | ||
| 2026-02-20 | SUMER JACQUELYN L Chief Legal Officer | Sale | −3,742 | $13.62 | $51K | 131,690 |
Page 2 of 23 · 446 trades